Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.842
Abstract: Two studies evaluated the effects of renal and hepatic impairment on pharmacokinetics and safety of rivipansel (NCT02813798, NCT02871570). A single intravenous 840‐mg rivipansel dose was administered to subjects with renal impairment or normal renal function… read more here.
Keywords: rivipansel; renal hepatic; hepatic impairment; impairment pharmacokinetics ... See more keywords
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2688
Abstract: Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk of progression to severe disease, including patients with chronic kidney disease. Because… read more here.
Keywords: impairment pharmacokinetics; nirmatrelvir ritonavir; impairment; renal impairment ... See more keywords
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.955
Abstract: Ertugliflozin is a highly selective and potent inhibitor of the sodium‐glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus. The glycemic efficacy of sodium‐glucose cotransporter 2 inhibitors such as ertugliflozin depends… read more here.
Keywords: effect renal; type diabetes; diabetes mellitus; impairment pharmacokinetics ... See more keywords